Business UpdateOct 29, 2026, 04:17 PM
Rezolute Releases Investor Presentation on Ersodetug Development
AI Summary
Rezolute, Inc. has released an investor presentation detailing its progress in developing ersodetug for refractory hypoglycemia. The company reported $108 million in cash with a runway through Q1 2028. While the Phase 3 sunRIZE study for congenital hyperinsulinism (HI) did not meet its primary endpoint, secondary endpoints showed clinically meaningful reductions in hypoglycemia, and the FDA has encouraged a pre-BLA meeting. The Phase 3 upLIFT study for tumor HI is expected to report topline results in mid-December 2026. The company estimates a global market opportunity exceeding $5 billion.
Key Highlights
- Rezolute, Inc. released an investor presentation on October 29, 2026.
- The company has $108 million in cash with a runway through Q1 2028.
- Ersodetug is being evaluated for refractory hypoglycemia in congenital HI and tumor HI.
- Phase 3 sunRIZE study for congenital HI did not meet its primary endpoint but showed clinically meaningful reductions in hypoglycemia via CGM.
- The FDA encouraged Rezolute to request a Type B pre-BLA meeting for congenital HI.
- Phase 3 upLIFT study for tumor HI expects topline results in mid-December 2026.
- The total addressable market for ersodetug is estimated to exceed $5 billion globally.
- Rezolute is a late-stage ultra-rare disease company focused on treating refractory hypoglycemia.
Price Impact
More from RZLT